Login to Your Account



Fewer Blockbuster Drugs On Tap For Approval This Year

By Randall Osborne


Monday, February 21, 2005
"Miracle drug" is not a phrase bandied about lightly in biotechnology, but when key data for Avastin (bevacizumab), the antibody for colorectal cancer from Genentech Inc., were unveiled at the American Society of Clinical Oncology annual meeting in 2003, people were talking. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription